



STATE MEDICAID DUR BOARD MEETING  
 THURSDAY, May 8, 2014  
 7:00 a.m. to 8:30 a.m.  
 Cannon Health Building  
 Room 125



# MINUTES

**Board Members Present:**

Tony Dalpiaz, PharmD.  
 Jay Aldus, DDS  
 Mark Balk, PharmD.  
 Keith Tolman, M.D.  
 Michael Symond, M.D.

Jennifer Brinton, MD  
 Susan Siegfroid, M.D.  
 Mr. Kumar Shah  
 George Hamblin, PharmD

**Board Members Excused:**

Kyle Jones, M.D.

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Robyn Seely, PharmD.  
 Trevor Smith C.Ph.T.  
 Merelynn Berrett, R.N.  
 Tim Morley, R.Ph.

Lisa V Hunt, R.Ph.  
 Heather Santacruz, R.N.  
 Richard Sorenson, R.N.

**Other Individuals Present:**

Joanita Lake, UofU  
 Gary Oderda, UofU  
 Edie Dodson, Genzyme  
 Scott Larson, BMS

Anne Marie Licos, MedImmune  
 Chris Desimone, Aegerion  
 Rob Halter, Aegerion  
 Sean Mcgarr, Forest

---

**Meeting conducted by: Tony Dalpiaz, Pharm.D.**

---

1. **Welcome** – Tony Dalpiaz opened the meeting.
2. **Housekeeping** – Robyn Seely said that there will be petitions following the meeting. She announced that the September meeting will be cancelled. She also reminded the board to sign in.
3. **P&T Committee report** – Lisa Hunt addressed the board she reported that the P&T committee reviewed the epinephrine pen formulation products. She said that the antihistamines 1<sup>st</sup> and 2<sup>nd</sup> generation products would be reviewed in the May meeting.
4. **Approval of prior meeting minutes** – Keith Tolman made a motion to approve the April minutes. Mark Balk seconded the motion. All others in favor.
5. **Hepatitis C Update** – Robyn Seely presented some additional guidelines about the new Hepatitis C products. She said that she would like to revisit the Hepatitis C drugs to

discuss the new guidelines and any criteria that should apply to the drug. She provided the board members with the new guidelines and told them to review it for discussion in the June DUR meeting.

6. **Homozygous Familial Hypercholesterolemia Drug Review** (Juxtapid and Kynamro) – Joanita Lake presented drug information, indications, studies, side effects and safety and efficacy data on the drugs (Juxtapid and Kynamro).

7. **Public Comment**

- a. **Rob Holter, (Aegerion, Juxtapid)** – Reported drug information and clinical trials about Daliresp, and answered questions from the board members.
- b. **Chris Desimone, (Aegerion, Juxtapid)** – Answered questions from board members.
- c. **Edie Dodson, (Genzyme, Kynamro)** - Answered questions from board members.

8. **Board Discussion**

- a. Keith Tolman shared some of the history of this disease and how the medication developed.
  - b. Mark Balk said that because of no past usage of these drugs with any Medicaid client, a PA is not necessary.
  - c. Tim Morley said that even with no usage, a PA can still be placed on the drug to ensure potential future patients follow the guidelines, especially with some safety concerns on the drugs.
  - d. Robyn Seely presented criteria based on the prescribing guidelines to the board for discussion.
  - e. Discussion by board members about the requirement of genetic testing on the PA form. There is a possibility of 20% false results on the genetic testing. They said that the drug would most likely be prescribed based on a diagnosis by observation, not simply a genetic test.
  - f. Mike Symond said that he thinks most providers will still do the genetic test to try to pinpoint the diagnosis. He said that the genetic test should be used, but the result of the test should not be the final decision in allowing the prescription to process.
  - g. Rob Holter, representative from Aegerion, added that genetic testing is not standardized, and that multiple mutations can cause the disease. Different labs will test for different mutations, which can cause unreliable results in the testing.
  - h. Mark Balk makes a motion that no prior authorization should be placed on the drug, and after nine months, the drug should be reviewed for usage and if necessary, a PA could be placed on it at that time. Mike Symond seconded the motion. Jennifer Brinton abstained from the vote. All other members in favor.
9. Meeting Adjourned – Keith Tolman voted to close the meeting. Jennifer Brinton seconded the motion. All in favor of closing the public meeting.

The next DUR Board meeting is scheduled for Thursday, June 12, proton pump inhibitors. Minutes prepared by Trevor Smith.

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)